Camptothecins in Cancer Therapy
Clinical interest in the camptothecins continues to expand even though this class of topoisomerase I inhibitors has been studied for almost 50 years, and two early generation members of the family have gained FDA approval. In Camptothecins in Cancer Therapy, leading clinicians and researchers critic...
| Συγγραφή απο Οργανισμό/Αρχή: | |
|---|---|
| Άλλοι συγγραφείς: | , |
| Μορφή: | Ηλεκτρονική πηγή Ηλ. βιβλίο |
| Γλώσσα: | English |
| Έκδοση: |
Totowa, NJ :
Humana Press,
2005.
|
| Σειρά: | Cancer Drug Discovery and Development
|
| Θέματα: | |
| Διαθέσιμο Online: | Full Text via HEAL-Link |
Πίνακας περιεχομένων:
- Biochemistry, Pharmacology, and Chemistry
- Mechanism of Action of Topoisomerase 1 Poisons
- Crystallographic Insight Into the Mechanism of Drug-Induced Topoisomerase I DNA Damage
- Inhibitors of Topoisomerase I Function
- Cytotoxic Mechanisms of Topoisomerase 1 Inhibitors
- Biochemical and Genetic Analyses of DNA Topoisomerase 1-Mediated DNA Damage
- Preclinical Models for Evaluating Topoisomerase I-Targeted Drugs
- Mechanisms of Resistance to Camptothecins
- Recent Advances in Camptothecin Drug Design and Delivery Strategies
- Clinical Perspectives
- Clinical Experience With 9-Aminocamptothecin
- Clinical Studies of Rubitecan (9-Nitro 20(S) Camptothecin)
- Irinotecan
- Clinical Experience With Topotecan
- The Clinical Development of Lurtotecan
- Preclinical and Clinical Development of Exatecan (DX-951f)
- Camptothecins in the Treatment of Primary Brain Tumors
- Camptothecins in the Treatment of Lung Cancer
- Use of Camptothecins in the Treatment of Leukemia and Related Disorders.